KENGREAL Rx

Select the drug indication to add to your list

KENGREAL

Thromboembolic disorders
Only 4 drugs may be compared at once

Generic Name and Formulations:

Cangrelor 50mg/vial; lyophilized pwd for IV inj after reconstitution and dilution; contains mannitol, sorbitol.

Select therapeutic use:

Indications for KENGREAL:

As adjunct to percutaneous coronary intervention (PCI) for reducing the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor.

Adult:

Initially 30mcg/kg IV bolus prior to PCI, followed immediately by 4mcg/kg/min IV infusion; continue infusion for ≥2hrs or for duration of PCI, whichever is longer. Transitioning to oral P2Y12 therapy: see full labeling.

Children:

Not established.

Contraindications:

Significant active bleeding.

Warnings/Precautions:

Increased risk of bleeding. Pregnancy (Cat.C). Nursing mothers.

Interactions:

Do not administer clopidogrel or prasugrel during infusion.

Pharmacological Class:

P2Y12 platelet inhibitor (ATP analog).

Adverse Reactions:

Bleeding, renal impairment, dyspnea, hypersensitivity reactions.

Generic Availability:

NO

How Supplied:

Single-use vial (10mL)—1, 10

KENGREAL 50mg vials (Qty:1)

appx. price $783.00